GEXVal Featured in BioCentury Article
wpmaster
株式會社GEXVal
December 22, 2025
GEXVal Featured in BioCentury Article “Raising the Sun: Japan Biotech Looks to Level Up”
GEXVal Inc. (President and CEO: Juran Kato, PhD; Location: Fujisawa, Kanagawa, Japan, hereinafter “GEXVal”) is pleased to announce that the Company was featured in BioCentury’s article Raising the Sun: Japan Biotech Looks to Level Up."
■ Article Overview
The article analyzes Japan's biotech industry as it enters a transformative phase, highlighting the emergence of next-generation Japanese biotech companies positioned for global markets. GEXVal was recognized as one of the few pharma spin-offs that has maintained independence while achieving sustained growth.
■ GEXVal's Global Approach Recognized
The article highlights GEXVal's unique position as a rare example of a Japanese biotech company led by a female CEO, noting the Company's global expansion through its Australian subsidiary for clinical development and active presence at industry conferences worldwide. The article also featured insights from President and CEO Dr. Kato on the distinctive characteristics and competitive strengths of Japanese biotech companies.
**Article Details**
|
Title |
Raising the sun: Japan biotech looks to level up |
|
Publication Date |
December 20, 2025 |
|
URL |
https://www.biocentury.com/article/657543/raising-the-sun-japan-biotech-looks-to-level-up |
[About BioCentury]
BioCentury is a leading U.S.-based media platform specializing in analysis and insights for the biopharmaceutical industry. Covering critical topics from drug discovery and clinical development to market dynamics and financing, BioCentury provides in-depth data analysis and expert reporting that serves as a trusted resource for strategic decision-making by industry professionals worldwide.
[About GEXVal]
GEXVal strives to create and develop innovative pharmaceuticals for unmet medical needs, ensuring Treatment Reaches the Unreached with focus on rare diseases and underserved medical conditions. By leveraging our proprietary AI-powered pharmacoinformatics technology, we illuminate paths to breakthrough therapies, identifying hidden potential in drug candidates to deliver life-changing medicines that bring new hope to patients and their families.
有關本事宜請諮詢:
Head of Corporate Office
Atsushi Sugizaki
info@gexval.com
